Financhill
Back

Ligand Pharmaceuticals Quote, Financials, Valuation and Earnings

Ligand Pharmaceuticals Price Quote

$70.57

Ligand Pharmaceuticals Key Stats

Sell
34
Ligand Pharmaceuticals (LGND) is a Sell

Day range:
$70.43 - $72.09
52-week range:
$49.24 - $94.57
Dividend yield:
0%
P/E ratio:
24.00
P/S ratio:
9.51
P/B ratio:
1.78%

Volume:
88.2K
Avg. volume:
183K
1-year change:
-9.02%
Market cap:
$1.2B
Revenue:
$131.3M
EPS:
$2.9

How Much Does Ligand Pharmaceuticals Make?

Is Ligand Pharmaceuticals Growing As A Company?

Ligand Pharmaceuticals Stock Price Performance

What Is Ligand Pharmaceuticals 52-Week High & Low?

Ligand Pharmaceuticals Price To Free Cash Flow

Data Unavailable

Is It Risky To Buy Ligand Pharmaceuticals?

Is Ligand Pharmaceuticals Cash Flow Positive?

  • What Is LGND Cash Flow From Operations?
    Cash flow from operations (TTM) is $49.6M
  • What Is Ligand Pharmaceuticals’s Cash Flow From Financing?
    Cash flow from financing (TTM) is -$59.9M
  • What Is Ligand Pharmaceuticals’s Cash Flow From Investing?
    Cash flow from investing (TTM) is -$11.7M

Ligand Pharmaceuticals Return On Invested Capital

  • Is Management Doing A Good Job?
    LGND return on invested capital is 7.6%
  • What Is Ligand Pharmaceuticals Return On Assets?
    ROA measures how assets are converting to revenues and is 6.71%
  • What Is LGND Return On Equity?
    ROE is a measure of profitability and is 7.96%

Ligand Pharmaceuticals Earnings Date & Stock Price

Ligand Pharmaceuticals Competitors

Ligand Pharmaceuticals Dividend Yield

Data Unavailable

Ligand Pharmaceuticals Analyst Estimates

YoY Growth Past Surprise
EPS: 0% 108.85%
Revenue: -44.22% 9.58%

Analyst Recommendations

Buy Recommendations: 2
Hold Recommendations: 0
Sell Recommendations: 0
Price Target: 116.80
Upside from Last Price: 65.51%

Major Shareholders

  • How many LGND shares are owned by institutional investors?
    29.8M LGND shares are owned by institutional investors
  • How many LGND shares are owned by insiders?
    2M LGND shares are owned by insiders